ArticleHypertension research : official journal of the Japanese Society of Hypertension2026
Achieved home systolic blood pressure and cardiovascular risk in older hypertensive patients.
Article in Hypertension research : official journal of the Japanese Society of Hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intensive blood pressure treatment reduces cardiovascular events, but the optimal achieved home systolic blood pressure (SBP) level for older patients with hypertension remains uncertain. This secondary analysis was based on data from the Strategy of Blood Pressure Intervention in Older Hypertensive Patients trial. Morning and evening home blood pressure measurements obtained between 3 and 12 months after enrollment were used to calculate the achieved home SBP. Participants were then categorized into four achieved home SBP groups: <125 mmHg, 125-130 mmHg, 130-135 mmHg, and ≥135 mmHg. The primary outcome was a composite of cardiovascular events. Among 7681 participants included in this analysis, 261 primary events occurred during the median follow-up of 3.43 years. Compared with home SBP ≥ 135 mmHg, the absolute risk reduction for the primary composite outcome was 1.70% in the <125 mmHg group, 1.36% in the 125-130 mmHg group. In multivariable analyses, home SBP < 125 mmHg and 125-130 mmHg were associated with lower risks of the primary composite outcome, with adjusted HRs of 0.62 (95% CI, 0.42-0.90) and 0.66 (95% CI, 0.47-0.94), respectively. Similar protective associations were observed for stroke (adjusted HR, 0.36; 95% CI, 0.19-0.66). Lower home SBP categories were not associated with a statistically significant increase in the primary safety outcome. These findings suggest that achieving home SBP below 130 mmHg, and further approaching 125 mmHg in selected patients with a high risk of stroke and good treatment tolerance, may provide additional cardiovascular benefit beyond the conventional threshold.
Indexed as
Identifiers
42660976What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.